Literature DB >> 34721715

Imaging in Tumor Immunology.

Euishin Edmund Kim1,2,3, Hyewon Youn2,4, Keon Wook Kang2,4,5.   

Abstract

Recent advances in immune modulation have made impressive progress in cancer immunotherapy. Because dynamic nature of the immune response often makes it difficult to evaluate therapeutic outcomes, innovative imaging technologies have been developed to enable non-invasive visualization of immune cells and tumors in their microenvironment. This review summarizes the current tumor immunology and describes new innovative imaging methods with great potential to obtain non-invasive real-time insights into the complex functions of the immune system and into the management of cancer immunotherapy. © Korean Society of Nuclear Medicine 2021.

Entities:  

Keywords:  Cancer immunotherapy; Imaging; Microenvironment; Tumor immunology

Year:  2021        PMID： 34721715      PMCID： PMC8517056          DOI： 10.1007/s13139-021-00706-6

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  82 in total

Review 1.  The journey from discoveries in fundamental immunology to cancer immunotherapy.

Authors:  Jacques F A P Miller; Michel Sadelain
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

2.  A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.

Authors:  Walayat Shah; Xiaofei Yan; Li Jing; Yi Zhou; Hongwei Chen; Yili Wang
Journal:  Cell Mol Immunol       Date:  2010-11-22       Impact factor: 11.530

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.

Authors:  S Wu; K Rodabaugh; O Martinez-Maza; J M Watson; D S Silberstein; C M Boyer; W P Peters; J B Weinberg; J S Berek; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1992-03       Impact factor: 8.661

5.  Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma.

Authors:  Z Dong; R Kumar; X Yang; I J Fidler
Journal:  Cell       Date:  1997-03-21       Impact factor: 41.582

Review 6.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 7.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Authors:  Deepak Mittal; Matthew M Gubin; Robert D Schreiber; Mark J Smyth
Journal:  Curr Opin Immunol       Date:  2014-02-14       Impact factor: 7.486

8.  Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Authors:  Nirav N Shah; Sarah J Nagle; Drew A Torigian; Michael D Farwell; Wei-Ting Hwang; Noelle Frey; Sunita D Nasta; Daniel Landsburg; Anthony Mato; Carl H June; Stephen J Schuster; David L Porter; Jakub Svoboda
Journal:  Cytotherapy       Date:  2018-10-29       Impact factor: 5.414

Review 9.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 10.  The immune response to tumors as a tool toward immunotherapy.

Authors:  F Pandolfi; R Cianci; D Pagliari; F Casciano; C Bagalà; A Astone; R Landolfi; C Barone
Journal:  Clin Dev Immunol       Date:  2011-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.